Effect of Combination Therapy with Extended-Release Metformine and Glimepiride on Carbohydrate and Lipid Metabolism in Patients with Type 2 Diabetes Mellitus

Main Article Content

V.I. Pankiv


The aim of investigation — to study the efficiency and safety of the therapy with extended-release metformine combined with glimepiride in patients with type 2 diabetes mellitus (DM). Materials and methods. There were 35 patients with type 2 DM under a supervision. Before inclusion in the study, patients received metformine without the achievement of target glycemic levels, and from the moment of supervision a combined hypoglycemic therapy with glimepirtide and extended-release metformine (Duglimax, manufactured by Kusum Pharm, Ukraine) was additionally administered in combination with metformine (Metamine SR, manufactured by Kusum Pharm, Ukraine). The treatment duration was 12 weeks. The indices of carbohydrate, lipid metabolism, the degree of insulin resistance and body weight were evaluated before and after the treatment. Results. As a result of the research, the positive effect of the combined therapy with glimepiride and metformine on the carbohydrate and lipid metabolism and, in total, on the risk factors of cardiovascular complications (dislipidemia, insulin resistance, hyperinsulinemia) has been established. The level of glycated hemoglobin compared with baseline values has reduced by 1.5 % (p < 0.05), fasting glucose — by 32.1 % (p < 0.05), postprandial glycemia — by 43.7 % (p < 0.05). In addition, the therapy was associated with improved lipid metabolism: reduction of total cholesterol by 16.6 % (p < 0.05), low-density lipoprotein cholesterol — by 29.7 % (p < 0.05), triglycerides — by 42.7 % (p < 0.001). There was a decrease in leptin level in the blood plasma from 17.84 ± 2.30 ng/ml to 14.83 ± 2.42 ng/ml (p > 0.05). Changes of anthropometric parameters (body mass index, waist and hip circumference) were not statistically significant (p > 0.05). Against the background of combined treatment, there were not registered hypoglycemic reactions and side effects. Conclusions. Combination hypoglycemic therapy with extended-release metformin and glimepiride during 12 weeks resulted in a statistically significant improvement of carbohydrate and lipid metabolism.

Article Details

How to Cite
Pankiv, V. “Effect of Combination Therapy With Extended-Release Metformine and Glimepiride on Carbohydrate and Lipid Metabolism in Patients With Type 2 Diabetes Mellitus”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), no. 5.77, Oct. 2016, pp. 27-32, doi:10.22141/2224-0721.5.77.2016.78750.
Original Researches


Kharroubi A.T., Darwish H.M. Diabetes mellitus: The epidemic of the century // World J. Diabetes. — 2015. — ​Vol. 25(6). — ​P. 850-867. doi:10.4239/wjd.v6.i6.850.

Wilkin T.J. The accelerator hypothesis: a review of the evidence for insulin resistance as the basis for type I as well as type II diabetes // Int. J. Obes. (Lond.). — 2009. — ​Vol. 33. — ​P. 716-726. doi: 10.1038/ijo.2009.97.

Simmons R.K., Echouffo-Tcheugui J.B., Sharp S.J. et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial // The Lancet. — 2012. — ​Vol. 380(9855). — ​P. 1741-1748. doi: 10.1016/s0140-6736(12)61422-6.

Standards of Medical Care in Diabetes 2016 // Diabetes Care. — 2016. — ​Vol. 39 (Suppl. 1). — ​S1–S112. http://diabetesjournals.org/ content/39/Supplement_1.toc. DOI: 10.2337/diaclin.34.1.00

Pareek A., Chandurkar N.B., Salkar H.R. et al. Evaluation of efficacy and tolerability of glimepiride and metformin combination: a multicentric study in patients with type 2 diabetes mellitus, uncontrolled on monotherapy with sulfonylurea or metformin // Am. J. Ther. — 2013. — ​Vol. 20(1). — ​P. 41-47. doi: 10.1097/MJT.0b013e3181ff7c63.

Kim H., Kim D., Cha B. et al. Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea // J. Diabetes Investig. — 2014. — ​Vol. 5(6). — ​P. 701-708. doi: 10.1111/jdi.12201.

Kim B.H., Shin K.H., Kim J. et al. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers // Clin. Ther. — 2009. — ​Vol. 31(11). — ​P. 2755-2764. doi: 10.1016/j.clinthera.2009.11.001.

Zhu H., Zhu S., Zhang X. et al. Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: meta-analysis of randomized controlled trials // Diabeto­logy and Metabolic Syndrome. — 2013. — ​Vol. 5. — ​P. 70. doi: 10.1186/1758-5996-5-70.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 11 12 > >>